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  This study investigated the effect of negative expectations on self-reports of cognitive 
functioning, treatment satisfaction, and endorsement of a common, negative chemotherapy-
related stereotype in 56 adults who had completed systemic chemotherapy for cancer treatment. 
Participants were assigned to either a negative expectation group or a control group. The 
negative expectation group had the relationship between chemotherapy and cognitive deficits 
overtly brought to their attention, while the control group did not. Both groups completed self-
report measures of cognitive functioning and treatment satisfaction, and then rated their degree 
of identification with a chemotherapy-related stereotype. It was hypothesized that the 
experimental group would report more negative cognitive symptoms, less treatment satisfaction, 
and greater endorsement of the stereotype than the control group.  Results revealed no significant 
differences between the two groups on these measures. Mean scores for both groups indicated 
high ratings of cognitive functioning and treatment satisfaction, however on a different measure, 
participants from both groups endorsed a moderate level of cognitive difficulties. Potential 
explanations for this inconsistent finding will be discussed. Further investigation may add to 
existing knowledge about the influence of negative expectations on self-reported functioning and 
may help inform optimal methods of interacting with cancer patients and others with chronic 
disorders. 
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Do Negative Expectations Affect Self-Reported Cognitive Functioning and Treatment 
Satisfaction After Chemotherapy Treatment for Cancer? 
 Worldwide, there are approximately 14.5 million people alive today who are survivors of 
cancer (American Cancer Society, 2014). By 2024, that number is expected to reach nearly 19 
million (American Cancer Society, 2014). While rates of cancer diagnosis continue to rise, 
cancer mortality rates have declined due to factors such as increased screening, early detection, 
and advances in treatment. As ever more people survive a diagnosis of cancer, issues related to 
cancer survivorship become increasingly important.  
 Returning to the activities of daily life after treatment for cancer can be a difficult 
process. For example, persisting physical symptoms such as fatigue and pain may impede a 
successful transition back to the workplace or to school (Horneber, Fischer, Dimeo, Ruffer, & 
Weis, 2012; Pertl, Quigley, & Hevey, 2014). Psychological symptoms such as anxiety and 
depression are common experiences both during and after treatment and can negatively impact 
the recovery process for cancer survivors (Hinz, Krauss, Hauss, Hockel, Kortmann, Stolzenburg, 
& Schwartz, 2010; Linden, Vodermaier, MacKenzie, & Greig, 2012; Mitchell, Chan, Bhatti, 
Halton, Grassi, Johansen, & Meader, 2011; Raffa & Tallarida, 2010; Reyes-Gibby, Anderson, 
Morrow, Shete, & Hassan, 2012).  
Chemotherapy-Related Cognitive Impairment (CRCI) 
 Individuals undergoing, or who have undergone chemotherapy treatment for cancer, 
frequently describe negative changes in their cognitive abilities (Ahles & Saykin, 2007; 
Ferguson & Ahles, 2003; Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; Johnston, 2013; 
Porter, 2013; Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013; Simo, Rifa-
Ros, Rodriguez-Fornells, & Bruna, 2013). Colloquially referred to as “chemo-brain” (Mann, 
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1999) or “chemo-fog” (Mitchell & Turton, 2011; Raffa & Tallarida, 2010), chemotherapy-
related cognitive impairment, or CRCI (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou, 
& Kalofonos, 2011; Holmes, 2013), consists of a constellation of frequently reported symptoms 
that include problems with attention, concentration, and memory (Joly, Rigal, Noal & Giffard, 
2011; Matsuda, Takayama, Tashiro, Nakamura, Ohashi, & Shimozuma, 2005; Schagen, van 
Dam, Muller, Boogerd, Lindebloom, & Bruning, 1999; Vardy & Tannock, 2007; Wieneke & 
Dienst, 1995). A subset of cancer patients treated with chemotherapy (12-68%) demonstrate 
impairment on neuropsychological tests (Ahles & Saykin, 2007; Johnston, 2014; Joly, Rigal, 
Noal, & Giffard, 2011; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 2014; 
Shilling, Jenkins, & Trapala, 2006). Problems with attention, concentration, and memory may 
contribute to a lower quality of life after cancer diagnosis and treatment (Hodgson, Hutchinson, 
Wilson, & Nettelbeck, 2013; Meyers, 1999; Mitchell & Turton, 2011; Short, Vasey, & Tunceli, 
2005; Simo, Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013). Although cognitive difficulties after 
chemotherapy have been shown to diminish over time (Hodgson, Hutchinson, Wilson, & 
Nettelbeck, 2013; Hutchinson et al., 2012; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, 
& Talmi, 2014), Ahles and Saykin (2002) and Reneman, et al. (2011) demonstrated enduring 
cognitive deficits in a sample of cancer survivors more than 10 years after treatment had ended.   
History and Etiology of CRCI 
 It was likely Silberfarb, Philibert, and Levine (1980) who first reported a possible link 
between chemotherapy and declines in cognitive functioning. Silberfarb and colleagues 
administered cognitive tests (Trail Making Test B, Digit Symbol Coding, Cognitive Capacity 
Screening Test) and self-report measures (Self-Rating Depression Scale and Multiple Affect 
Adjective Check List) to 50 medical oncology patients. Results revealed cognitive impairment as 
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a “common occurrence” in the absence of affective disorders or other psychopathology 
(Silberfarb et al., 1980). Based on these findings, Silberfarb and colleagues identified 
chemotherapy as the underlying common factor amongst the patients and cautioned that 
consulting mental health providers be aware that changes in cognitive and emotional functioning 
may be due, in part, to treatment with chemotherapy (1980).  
 Inquiries regarding chemotherapy-related cognitive impairment (CRCI) have become 
increasingly complex and intensely debated since the work of Silberfarb, Philibert, and Levine 
(1980). While use of the term “chemo-brain” has become widespread among patients, medical 
providers, and researchers, its etiology is not well understood (Ahles & Saykin, 2001; Anderson-
Hanley, Sherman, Riggs, Agocha & Compas, 2003; Jansen, Miaskowski, Dodd, Dowling & 
Kramer, 2005; Wieneke & Dienst, 1995). Attempting to isolate the factors that contribute to 
CRCI has become a major challenge. Numerous biological and psychological factors likely 
interact to produce the phenomenon of CRCI. For example, cognitive impairments in individuals 
with cancer often occur alongside fatigue, pain, anxiety, and depression (Horneber, Fischer, 
Dimeo, Ruffler & Weis, 2012; Linden, Vodermaier, MacKenzie & Greig, 2012; Pertl, Quigley & 
Hevey, 2014; Singer et al., 2013; Spiegel & Giese-Davis, 2003). Consequently, there is 
uncertainty regarding whether CRCI should be considered a cause or a consequence of these 
negative affective states (Hermelink, 2011; Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 
2007; Tope, Ayles, & Silberfarb, 1993). The fact that not all patients experience cognitive 
deficits suggests that some patients may be more susceptible to CRCI than others. This 
susceptibility could be associated with many factors such as premorbid impairments, 
comorbidities, genetic predisposition, cancer type, and treatment protocol (Argyriou, 
Assimakopoulos, Iconomou, Giannakopoulou, & Kalofonos, 2011; Wefel, Saleeba, Buzdar, & 
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Meyers, 2010; Zucca, Boyes, Linden, & Girgis, 2012). The ability to identify the subset of 
patients most susceptible to CRCI would permit comprehensive treatment strategies before 
chemotherapy begins, such as establishing an individual’s baseline level of cognitive 
functioning, psycho-education around CRCI, psychotherapy for coping with emotional distress, 
and the addition of supportive pharmacotherapies (Joly, Rigal, Noal & Giffard, 2011; Raffa, 
2011). 
Measurement of CRCI 
 A thorough understanding of cognitive impairment after chemotherapy requires that 
changes in functioning be detected and measured. Perhaps the most universal and puzzling 
finding associated with the measurement of CRCI is the discrepancy that exists between 
individuals’ scores on self-report measures of cognitive functioning and their scores on 
neuropsychological measures of cognitive functioning (Bender, Sereika, Berga, et al., 2006; 
Evenden, 2013; Myers, 2012; Rugo & Ahles, 2003; Schilder et al., 2012; Weis, Poppelreuter, & 
Bartsch, 2009). It is common for survivors to self-report a high degree of cognitive impairment 
yet demonstrate minimal to moderate impairment on objective measures of cognitive functioning 
(Ferguson, McDonald, Saykin, & Ahles, 2007; Hodgson, Hutchinson, Wilson, & Nettelbeck, 
2013; Rugo & Ahles, 2003; Schilder et al., 2012). In numerical terms, 83% of individuals treated 
with chemotherapy self-report cognitive impairments (Jenkins et al., 2006; Kohli et al., 2006; 
O’Schaughnessy, 2003), yet only 12-68% demonstrate impairments on neuropsychological tests 
(Ahles & Saykin, 2007; Shilling, Jenkins, & Trapala, 2006). The lack of congruence between 
subjective and objective evaluations suggests that these evaluations are measuring either 
different facets of one construct, or two separate constructs (Hermelink et al., 2010; Hutchinson, 
Hosking, Kichenadasse, Mattiske & Wilson, 2012). The lack of a strong association between 
	 5	
scores on self-reports (subjective measures) and scores on neuropsychological tests (objective 
measures) may have multiple explanations. Methodological issues have been identified as 
contributing to the discrepancy between subjective and objective measurements of functioning 
(Kaiser, Bledowski, & Dietrich, 2014; Porter, 2013; Pullens, De Vries, Van Warmerdam, Van 
De Wal, & Roukema, 2013; Schagen et al., 2002; Schagen, 2007; Seigers & Fardell, 2011).  
Methodological Contributors to the Discrepancy in Findings 
Comparison Groups 
 One primary methodological problem faced by CRCI researchers lies in the selection of 
an appropriate comparison group to whom survivors’ scores are compared (Hodgson, 
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen et al., 2005; Kaiser, Bledowski, & Dietrich, 
2014; Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013; Schilder et al., 
2012). Group differences may cause patients’ scores on neuropsychological tests to appear 
“better” or “worse” depending on whether the scores are compared to those of healthy controls, 
cancer patients who received only localized treatment, or to patients’ own baseline levels of 
cognitive functioning. The last comparison (comparing patients to their own baseline) is 
particularly scarce in the literature, as a limited number of studies have successfully collected 
pre-chemotherapy data. Contributing to a lack of baseline data may be the pressure that patients 
feel to begin treatment following a life-threatening diagnosis (Hodgson, Hutchinson, Wilson, & 
Nettelbeck, 2013; Joly, Rigal, Noal, & Giffard, 2011; Mitchell & Turton, 2011; Stewart, 
Bielajew, Collins, Parkinson, & Tomiak, 2006). Neuropsychological findings based on within-
group comparisons have often not reached statistical significance (Jansen, Miaskowski, Dodd, 
Dowling, & Kramer, 2005; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 
2014). Some researchers have suggested that the small sample sizes used in this type of 
	 6	
comparison do not allow for sufficient power to detect an effect if one is there (Hodgson, 
Hutchinson, Wilson, & Nettelbeck, 2013; Porter, 2013; Seigers & Fardell, 2011). Other 
hypotheses that have been put forth to explain inconclusive findings propose that effects may 
vary with treatment type, treatment intensity and duration, and that effects may vary depending 
on when (during or after treatment) data are collected (Evenden, 2013; Hodgson, Hutchinson, 
Wilson, & Nettelbeck, 2013; Quesnel, 2009; Schilder, Eggens, Seynaeve, et al., 2009; Simo, 
Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013). Research indicates that the most striking effects 
occur either during, or shortly after treatment, however the duration of impairments is not well 
understood and effects have been found many years after treatment has ended (Ahles & Saykin, 
2002; Evenden, 2013; Mitchell & Turton, 2011; Monje & Dietrich, 2012; Porter, 2013; de Ruiter 
et al., 2011; Simo, Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013; Wigmore, 2013).  
Instrument-Related Confounds 
 A second methodological problem that could contribute to the discrepancy between 
scores on self-report and objective measures includes instrument-related confounds (Hodgson, 
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, & Dowling, 2007; 
Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 2014; Porter, et al., 2013; 
Schilder et al., 2012). One challenging problem when attempting to make comparisons across 
studies, regards the classification of neuropsychological tests to particular domains of cognitive 
functioning (Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, 
Dowling, & Kramer, 2005; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 
2014). Multiple tests can be used to measure a single cognitive domain and researchers differ in 
their preference for particular tests for particular domains. Consequently, it can be difficult to 
link individual tests with the scores that are provided. Lindner and colleagues (2014) suggest 
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guidelines that would facilitate the objective measurement of impairments in future studies. 
Examples that are germane to this discussion include the following guidelines: the use of shorter 
neuropsychological batteries that specifically focus on certain cognitive functions; when using 
neuropsychological tests, strive to use very similar versions of the same cognitive tests between 
research groups and report the same scores; and consistently group test scores into cognitive 
functions, as the high number of neuropsychological tests makes it difficult to understand 
whether two different results refer to the same function (Lindner, Phillips, McGabe, Mayes, 
Wearden, Varese, & Talmi, 2014). 
 A second instrument-related problem includes the use of measures that are insensitive to 
mild to moderate impairments (Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 2007; 
Mitchell & Turton, 2011; Porter, 2013). Neuropsychological measures that are used to capture 
more profound deficits in cognitive functioning, such as The Mini Mental State Examination, are 
of little use in the detection of mild to moderate cognitive changes (Evens & Eschiti, 2009; 
Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 20142014; Meyers, Geara, 
Wong, & Morrison, 2000; Mitchell and Turton, 2011). As research continues, it will become 
imperative to establish a consistent neuropsychological battery that is both brief, sensitive, and as 
resistant to practice effects as possible (Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; 
Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 2007; Lindner, Phillips, McGabe, Mayes, 
Wearden, Varese, & Talmi, 2014; Vardy, Wefel, Ahles, Tannock, & Schagen, 2008).  
 Numerous factors limit the detection and objective measurement of impairments in 
cognitive functioning after chemotherapy. The two broad methodological problems discussed 
above (appropriate comparison groups and instrument-related confounds) should also be 
considered within the larger context of CRCI research in general. The systematic study of the 
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effect of chemotherapy on cognitive functioning is in its early stages. There are only a handful of 
meta-analyses that offer effect sizes for the effect of chemotherapy on specific domains of 
cognitive functioning (Falleti, Sanfilippo, Maruff, Weih, and Phillips, 2005; Hodgson, 
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, Dowling, & Kramer, 
2005; Stewert, Bielajew, Collins, Parkinson, & Tomiak, 2006) and these few meta-analyses base 
their effect sizes on scores on objective neuropsychological tests only. Direct comparisons 
between studies are often impractical because of inconsistencies in the literature about what to 
measure and how to measure it (Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003; 
Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005). Despite these challenging factors, 
conclusions based on objective neuropsychological testing have been put forth regarding the 
effects of chemotherapy on cognition.  
Neuropsychological Measurement of CRCI 
 Meta-analyses that have summarized the objective, neuropsychological findings of earlier 
studies have shown that individuals treated with chemotherapy demonstrate a wide range of 
small to moderate cognitive deficits when compared to normal controls. These deficits occur in 
the following areas: attention, processing speed, verbal and visual memory, long-term and 
working memory, visuospatial skills, executive functioning, and motor functioning (Anderson-
Hanley, Sherman, Riggs, Agocha, & Compas, 2003; Falleti, Sanfilippo, Maruff, Weih, & 
Phillips, 2005; Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005; Stewart, Bielajew, 
Collins, Parkinson, & Tomiak, 2006).  
 Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi (2014) built on the 
investigation of the objective measurement of cognitive functioning after chemotherapy by 
conducting a meta-analysis of the results from 44 studies published between 1980 and January 
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2011. Studies were subdivided into cross-sectional and longitudinal designs. Results from studies 
using cross-sectional designs showed impairments on immediate free recall, delayed memory, 
verbal memory, delayed recognition memory, selective attention, and attention capacity, with 
small effect sizes at or slightly above d = 0.20. Results from studies using longitudinal designs 
showed more moderate effect sizes across multiple functions, but that patients performed better 
in follow-up evaluations than at baseline (Lindner, Phillips, McGabe, Mayes, Wearden, Varese, 
& Talmi, 2014).  
Subjective Report versus Objective Measurement   
 A difference of opinion exists within CRCI literature regarding the etiology of the 
discrepancy between scores on self-report versus objective measures. Some research has 
attributed the difference in scores on objective versus subjective measures solely to flaws in 
methodology or issues in neuropsychological testing (Hermelink et al., 2010, Jansen, 
Miaskowski, Dodd, Dowling & Kramer, 2005; Shilling & Jenkins, 2007). For example, it has 
been proposed that if neuropsychological tests were improved, larger effects would be observed. 
Improvements in objective measures likely would increase the size of the observed effects, but 
may not fully explain the discrepancy between subjective objective measures. Alternatively, 
other research has considered scores on subjective measures to be the most accurate indicators of 
cognitive functioning (Hermelink et al., 2010). The utility of this perspective is limited by 
research that has demonstrated the effect of secondary factors (e.g., negative affective states like 
depression) on self-reports of functioning (Joly, Rigal, Noal, & Giffard, 2011; O’Connor et al., 
2012; Zucca, Boyes, Linden, & Girgis, 2012). In addition to cognitive impairment, self-reported 
negative symptoms may reflect factors such as the experience of emotional distress (depression, 
sadness, anxiety, fear, worry, anger, panic) involved in coping with a life-threatening disease 
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(Andrykowski, Lykins, & Floyd, 2008; Argyriou, Assimakopoulos, Iconomou, Giannakopoulou, 
& Kalofonos, 2011).  
Secondary Factors that Influence the Experience of CRCI 
 The literature is replete with examples of research that demonstrate the influence of 
secondary factors on test performance (Croizet & Claire, 1998; Levy, 1996; Spencer, Steele, & 
Quinn, 1999; Steele & Aronson; 1995, & Steele, 1997) and it is widely accepted that physical 
and psychological symptoms affect cognitive functioning (Joly, Rigal, Noal, & Giffard, 2011; 
O’Connor et al., 2012; Zucca, Boyes, Linden, & Girgis, 2012). For cancer survivors, the 
discrepancy between scores on objective versus subjective measures of cognitive functioning 
may be due, in part, to factors such as negative affective states. Undoubtedly, it is common for 
individuals to experience symptoms of depression and anxiety immediately following a 
diagnosis of cancer (Anderson, Golden-Kreutz, Emery, & Thiel, 2009; Andrykowski, Lykins, & 
Floyd, 2008; Hill et al., 2010; Mehnert et al., 2012; Spiegel & Giese-Davis, 2003), and numerous 
studies have reported an association between depression, anxiety, and cognitive complaints 
(Cimpich, Ronis, & Trask, 2005; Cull et al., 1996; Schagen, Boogerd, & Muller, 2008; Schagen, 
van Dam, Muller, Boogerd, Lindeboom, & Bruning,1999; Schilling & Jenkins, 2007, Velde, 
Linn, Nortier, Schilder, Seynaeve, Gundy, …& van Dam, 2012). Increased symptoms of 
depression and anxiety may serve to intensify the perception of negative cognitive symptoms 
after chemotherapy. 
Stereotype Threat 
 Another possible explanation for the discrepancy between scores on subjective and 
objective measures of functioning may be related to the idea of stereotype threat (Steele & 
Aronson, 1995). Steele and Aronson (1995) describe stereotype threat, “… as a social-
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psychological predicament that can arise from widely known stereotypes about one’s group,” 
(1995, p. 797). Stereotype threat occurs when a person experiences the threat of being judged or 
treated stereotypically, or fears fulfilling a stereotype (Steele & Aronson, 1995). Research in the 
field of social psychology has shown that the activation of a stereotype can greatly impact the 
way individuals think and behave (Hamilton & Sherman, 1994; Steele & Aronson, 1995; Steele, 
1997).  Stereotypes, or fixed schemas, can be described as mental representations of prior 
knowledge and experiences (Kunda, 1999; Schagen, Das, & van Dam, 2009). These schemas can 
be made accessible through the process of priming, whereby contextual information is provided 
to the individual that results in the activation of the mental representation or stereotype (Steele, 
1997). Both positive and negative stereotypes may be activated. For example, Margaret Shih and 
colleagues (2002) showed that activation of a positive stereotype “boosted” performance for 
Asian students on a math test when this positive stereotype was subtly called to their attention 
(Shih, M., Ambady, N., Richeson, J. A., Fujita, K., & Gray, H. M., 2002). Conversely, Kaye & 
Pennington (2016) examined the performance of females and males on a computer gaming task 
where females were told (prior to the task) that they have been shown to underperform males on 
various gaming tasks. Results showed that females performed more poorly than males (negative 
stereotype activation) on the task (Kaye, L. K., & Pennington, C. R., 2016). The process of 
activating a negative stereotype is referred to as stereotype threat (Steele & Aronson, 1995).  
 One of the first published examples of Stereotype Threat involved a series of experiments 
that focused on Black and White students and intellectual test performance (Steele & Aronson, 
1995). The experimental group consisted of both Black and White students. This group was told 
that their performance on a test (Graduate Record Exam (GRE) items) would be diagnostic of 
academic ability. This statement served to make negative racial stereotypes about the intellectual 
	 12	
ability of Blacks salient to Black participants. The control group also consisted of Black and 
White students. This group was not told that the test measured academic ability before taking the 
test. Results showed that Black students performed more poorly than White students under the 
threat condition (being told the test measured academic ability), but matched White students 
under the neutral condition (not being told the test measured academic ability). This study clearly 
demonstrated the power of Stereotype Threat; negative expectations affected African Americans’ 
performance and served to lower their scores. The influence of negative expectations on test 
performance has been demonstrated extensively in the literature (Croizet & Claire, 1998; Levy, 
1996; Spencer, Steele, & Quinn, 1999; Suhr & Gunstad, 2002; Suhr & Gunstad, 2005; Steele & 
Aronson; 1995, & Steele, 1997). 
Diagnosis Threat 
 In 2002, Suhr and Gunstad applied the concept of negative expectancies to the study of 
traumatic brain injury (TBI). Suhr and Gunstad recruited participants with a previous diagnosis 
of TBI. The participants, who all had a prior history of TBI, were assigned to either the 
experimental group or the control group. Participants in the experimental group (N = 17) were 
told that individuals with a history of prior TBI would likely perform poorly on measures of 
cognitive functioning due to their prior TBI, whereas participants in the control group (N = 19) 
were simply told to put forth their best effort. Both groups completed measures of functioning 
(memory, intellect, attention, and psychomotor speed) and the results were compared. The 
experimental group did, in fact, perform more poorly than the control group on objective 
measures of cognitive functioning. Because decrements in performance were observed following 
activation of negative expectations related to a prior diagnosis, Suhr and Gunstad named this 
process diagnosis threat (2002).  
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 In 2005, Suhr and Gunstad continued their investigation of the effect of diagnosis threat 
on cognitive performance in a sample of college students with a history of mild TBI. Suhr and 
Gunstad wanted to know whether anxiety, effort, and depression in fact drive the experience of 
diagnosis threat. Participants were assigned to either a diagnosis threat condition (n = 28) or a 
control condition (n = 25). Participants completed measures of anxiety (State Trait Anxiety 
Inventory and a Likert scale that provided self-reported pressure during testing), measures of 
effort (Word Memory Test and a Likert scale that provided self-reported effort during testing), 
and a measure of depression (Beck Depression Inventory, Second Edition). Neuropsychological 
tests measured memory, psychomotor speed, attention, and executive functioning. Results were 
consistent with prior findings and demonstrated that those in the diagnosis threat condition 
performed worse than those in the control condition on neuropsychological tests. However, 
contrary to predictions, no differences arose between the groups on anxiety, effort, or depression. 
These findings suggest that anxiety, effort, and depression did not account for the differences 
between the groups on objective measures of functioning. Questions remain regarding the causes 
of diagnosis threat. Wheeler and Petty (2001) contend that activation of schemas related to a 
stereotype explains the experience of diagnosis threat more than affect or motivational changes 
due to that threat.  
 Trontel, Hall, Ashendorf, and O’Conner (2013) further explored diagnosis threat by 
examining its impact on academic self-efficacy and neuropsychological test performance in 
individuals with mild traumatic brain injury.  All participants had prior diagnoses of mild TBI 
and were randomly assigned to either a diagnosis threat group or a control group. Individuals in 
the diagnosis threat group were told that they were selected for participation based on their prior 
diagnosis of TBI, while those in the control group were told to perform to the best of their ability 
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(Trontel, Hall, Ashendorf, & O’Connor, 2013). Results revealed that the groups performed 
differently on just one objective neuropsychological measure. However, the participants in the 
diagnosis threat group self-reported significantly lower academic self-efficacy than participants 
in the control group. This finding suggests that diagnosis threat may have a larger impact on self-
report than on objective cognitive performance. 
Other Examples of Negative Expectations 
 In 2009, Schagen, Das, and van Dam examined CRCI using a diagnosis threat type of 
methodology. The researchers conducted interviews with patients at the Netherlands Cancer 
Institute.  Patients were interviewed about the occurrence of fatigue, insomnia, and memory and 
concentration problems. Patients were asked to rate the extent of each complaint using a 5-point 
Likert type scale, where 1 indicated ‘not at all,’ and 5 indicated ‘extremely.’  For half of the 
interviews, participants were told that ‘some patients treated with cytotoxic agents 
(chemotherapy) experience cognitive problems,’ and that the goal of the study was to ‘obtain 
more insight into the relationship between chemotherapy and cognitive problems. The other half 
of patients (the control group) received a neutral introduction with no mention of the association 
between chemotherapy and cognitive impairments. After the interviews, all patients were asked 
whether they were familiar with, or had knowledge of, the CRCI stereotype.  
 Results of this experiment were somewhat surprising. First, physical symptoms such as 
fatigue, insomnia, and limited endurance were the most frequently reported symptoms. Second, 
individuals with prior knowledge about the CRCI stereotype (those who had heard of the CRCI 
stereotype unrelated to the experiment) reported more complaints than individuals without prior 
knowledge of the CRCI stereotype regardless of the type of complaint (cognitive v. physical). 
And third, activating the CRCI stereotype had an overall greater effect on the cognitive 
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complaints made by individuals with no prior knowledge of the CRCI stereotype than those with 
prior knowledge of the CRCI stereotype (Schagen, Das, & van Dam, 2009).  This study 
demonstrated that activating the CRCI schema increased all individuals’ reports of cognitive 
complaints, and that these complaints increased most significantly for individuals with no prior 
knowledge of the CRCI schema.  This result suggests that patients with little to no knowledge 
about CRCI may be the most susceptible to the experience of CRCI. This finding is especially 
poignant in light of the fact that patients often report having received little pre-treatment 
education about the effects of chemotherapy on cognition (Evens & Eschiti, 2009; Mitchell & 
Turton, 2011; Myers, 2012; Porter, 2013, Schagen, Das, & van Dam, 2009).  
 Negative expectations related to treatment with chemotherapy may operate by a 
mechanism like that involved in negative expectations related to a prior diagnosis. Negative 
expectations related to treatment with chemotherapy may influence the degree and frequency 
with which cancer survivors report symptoms of cognitive decline. It may also be true that 
activation of negative expectations related to treatment produces effects that are not limited to 
cognitive functioning. Understanding the full impact of negative expectations on different 
aspects of survivors’ health may help inform pretreatment psycho-education strategies and peri- 
and post- treatment coping and remediation strategies. The current work sought to expand the 
investigation of negative expectations in cancer survivors by examining not only its impact on 
cognitive functioning in individuals who have received treatment with chemotherapy, but also its 
impact on treatment satisfaction, and endorsement of a chemotherapy-related stereotype both 
during and after treatment. It was hypothesized that individuals in the negative expectations 
group would report more negative cognitive symptoms, less treatment satisfaction, and greater 
endorsement of a chemotherapy-related stereotype than participants in the control group. 
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Hypotheses Related to Cognitive Functioning (Primary Hypotheses) 
1) Participants in the negative expectations group will report significantly more 
perceived cognitive impairments than participants in the control group, as measured 
by the mean scores of the two groups on the ‘Perceived Cognitive Impairments’ 
subscale of the FACT-Cog (Version 3).  
2) Participants in the negative expectations group will report significantly more negative 
comments from others about their cognitive functioning than participants in the 
control group, as measured by the mean scores of the two groups on the ‘Comments 
From Others’ subscale of the FACT-Cog (Version 3). 
3) Participants in the negative expectations groups will report significantly fewer 
cognitive abilities than participants in the control group, as measured by the mean 
scores of the two groups on the ‘Cognitive Abilities’ subscale of the FACT-Cog 
(Version 3). 
4) Participants in the negative expectations group will report that perceived cognitive 
impairments have a significantly greater negative impact on quality of life than 
participants in the control group as measured by the mean scores of the two groups on 
the ‘Impact on Quality of Life’ subscale of the FACT-Cog (Version 3). 
Hypotheses Related to Treatment Satisfaction 
5) Participants in the negative expectations group will report significantly lower scores 
related to satisfaction with physician communication than the control group, as 
measured by the mean scores of the two groups on the ‘Physician Communication’ 
subscale of the FACIT-TS-PS (Version 4). 
6) Participants in the negative expectations group will report significantly lower scores 
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related to satisfaction with treatment staff communication than the control group, as 
measured by the mean scores of the two groups on the ‘Treatment Staff 
Communication’ subscale of the FACIT-TS-PS (Version 4). 
7) Participants in the negative expectations group will report significantly lower scores 
related to overall treatment satisfaction than will the control group as measured by the 
mean total scores of the groups on the FACIT-TS-PS (Version 4). 
Hypotheses related to Endorsement of a Chemotherapy-Related Stereotype  
8) Participants in the negative expectations group will report greater endorsement of a 
stereotype during treatment than participants in the control group, as measured by the 
mean scores on the Perceived Impairments Scale during treatment. 
9) Participants in the negative expectations group will report greater endorsement of a 
stereotype after treatment than will participants in the control group, as measured by 
mean scores on the Perceived Impairments Scale after treatment. 
Method 
Participants 
A total sample of 56 male and female participants between the ages of 25 years and 93 
years (M = 63.7 years, SD = 15.38) was collected over a three-month period at an outpatient 
cancer treatment center in the northwestern United States. Participants received a gift card valued 
at $20.00 for participation in the study. All participants were 18 years of age or older, had 
completed chemotherapy for the treatment of cancer prior to study participation, were not 
between courses of treatment, and were not entering palliative care.  
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Instruments 
Demographic Questionnaire (see Appendix A)  
 The demographic questionnaire includes questions about the participant’s age, education, 
psychological history (such as prior diagnoses and treatment), medical history (such as prior 
neurological conditions or history of traumatic brain injury), and oncology history (such as type 
of cancer, treatment duration, and time since last treatment). 
Instructions for Negative Expectations Group (see Appendix B) 
 Participants in the negative expectations group will be told in writing that they were 
chosen to participate due to their prior diagnosis of cancer and treatment with chemotherapy. The 
instructions will draw their attention to the fact that some oncology patients report experiencing 
problems with thinking and memory after chemotherapy. The instructions will then ask 
participants to complete the self-report questionnaires as thoroughly and accurately as possible. 
Participants in the negative expectations group will be asked to sign a form indicating that they 
read and understood the instructions. 
Instructions for Control Group (see Appendix C)  
 Instructions for the control group will not overtly draw participants’ attention to the 
relationship between chemotherapy and cognitive impairments. Instructions will simply ask 
participants in the control group to complete all questionnaires as thoroughly and accurately as 
possible. Control group participants will be asked to sign a form indicating that they read and 
understood the instructions. 
Self-Report Measures (see Appendices D and E) 
 The self-report measures that will be used in the current study are a part of the Functional 
Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by David 
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Cella, Ph.D. and colleagues. The FACIT Measurement System includes a range of health-related, 
quality of life questionnaires for individuals with chronic illnesses. The questionnaires have been 
validated and are targeted for the management of chronic illness. A subset of FACIT 
questionnaires, The Functional Assessment of Cancer Therapy (FACT) instruments, were 
specifically designed to assess cancer therapy and have been validated for use with individuals 
who are currently receiving treatment and with individuals who have finished receiving 
treatment (Cella et al., 1993; Webster, Cella, & Yost, 2003; Webster, Odom, Peterman, Lent, & 
Cella, 1999, Yellen, Cella, Webster, Blendowski, & Kaplan, 1997). 
The FACT-Cognitive Function (Version 3) is a self-report measure consisting of four 
subscales: ‘Perceived Cognitive Impairments’ (PCI) with 20 items, ‘Impact On Quality Of Life’ 
(IQOL) with 4 items, ‘Comments From Others’ (CFO) with 4 items, and ‘Perceived Cognitive 
Abilities’ (PCA) with 9 items. Participants were asked to indicate the frequency with which they 
experienced symptoms on each of the four scales over the course of the previous week. Response 
options included: ‘Never’, ‘About once a week’, ‘Two to three times a week’, ‘Nearly every 
day’, and ‘Several times a day’. Negatively worded items on the FACT-Cog are reverse-scored 
such that higher scores on this measure indicate better functioning. Per FACT-Cog, V3 scoring 
guidelines, adding subscale scores to obtain total scores is not applicable. Internal consistency 
reliability coefficients for PCI, IQOL, CFO, and PCA scales were r = .94, r = .67, r = .90, and r 
= .92, respectively. Test-retest reliability coefficients for the PCI, IQOL, CFO, and PCA scales 
were r = .82, r = .82, r = .79, and r = .86, respectively. Wagner et al. (2008) found good to 
excellent convergent validity (>.70) with the Cognitive Difficulties Scale (CDS), another 
frequently used self-report measure of cognitive functioning.  
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The FACIT-TS-PS (Version 4) is a self-report measure of patient treatment satisfaction. 
The FACIT-TS-PS (Version 4) includes six scales: ‘Physician Communication,’ ‘Treatment 
Staff Communication,’ ‘Technical Competence,’ ‘Nurse Communication,’ ‘Confidence and 
Trust,’ and ‘Overall’ treatment satisfaction. Two subscales ‘Physician Communication’ and 
‘Treatment Staff Communication’ along with the FACIT-TS-PS Total Score were selected for 
analyses. Participants were asked to indicate the quality of the health care services that they 
received over the course of their medical care. Response options included: ‘No, not at all,’ ‘Yes, 
but not as much as I wanted,’ ‘Yes, almost as much as I wanted,’ and ‘Yes, and as much as I 
wanted.’ Negatively worded items on the FACIT-TS-PS, V4 are reverse-scored such that higher 
scores on this measure indicate greater treatment satisfaction. Reliability and validity data are 
not available for this measure. 
Perceived Impairments Scale (see Appendix F)  
 This scale consisted of two items and was used to assess the degree to which participants 
endorsed a chemotherapy-related stereotype during and after treatment. Specifically, participants 
rated how accurately a description of negative cognitive symptoms (based on a common 
chemotherapy-related stereotype) represented their experience 1) during treatment, and 2) after 
treatment. A seven-point Likert scale was used for these two items, where a rating of 0 indicated 
‘not accurately at all’ and a rating of 7 indicated ‘perfectly accurately.’  
Debriefing Statement (see Appendix G) 
 A debriefing statement was provided to participants at the end of the study. This form 
included information about the purposes of the study and provided contact information for the 
researcher if the participant had questions or concerns regarding participation. 
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Design and Procedures 
Overview 
Participants were recruited via flyers provided by physicians during patients’ regularly 
scheduled maintenance appointments. Participants were randomly assigned to either an 
experimental group or a control group and completed all questionnaires on-site in a quiet 
location. Participation took approximately 20 minutes and was followed by debriefing and 
receipt of gift card. 
Procedure  
At the study appointment, participants were escorted to a quiet location on-site where 
they completed the Informed Consent Form and the Demographic Questionnaire. Each 
participant was then given an envelope with a letter inside that contained study instructions that 
also served to assign participants to either an experimental or control group. Participants in the 
experimental group were informed by their letter that they were selected for participation due to 
their prior cancer diagnosis and treatment with chemotherapy. Participants in the experimental 
group also had the relationship between chemotherapy and cognitive impairment brought to their 
attention by reading a short paragraph describing CRCI (see Appendix B).  These statements 
were intended to activate treatment threat in the experimental group prior to completion of the 
self-report measures. Participants in the control group were simply instructed to complete the 
self-report measures as thoroughly and accurately as possible (see Appendix C). The examiner 
exited the room while the participants read the instructions, thereby ensuring that the examiner 
was unaware of group assignment at the time of participation. After reading the instructions, 
participants were required to sign them, place them back into the envelope, and seal the 
envelope. The examiner then re-entered the room and administered the following self-report 
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measures: the FACT-Cognitive, Version 3 (FACT-Cog, V3) the FACIT-Treatment Satisfaction-
Patient Satisfaction, Version 4(FACIT-TS-PS, V4) and the Perceived Impairments Scale. The 
session concluded with a debriefing statement (see Appendix G) and distribution of a gift card 
valued at $20.00. 
Results 
Participant Demographics 
Gender, Age, and Education 
Of the 56 total participants, 26 participants (46.4%) were women and 30 participants 
(53.6%) were men. A chi-square goodness-of-fit test indicated no significant difference in the 
proportion of males and females identified in the current sample compared with a sample 
composed of 50% males and 50% females, X2 (1, n = 56) = .29, p = .593. Results of the chi-
square goodness-of-fit test are shown below in Tables 1A and 1B. 
Table 1A. Chi-Square Gender Frequencies 
Gender Observed n Expected n Residual 
Male 30 28.0 2.0 
Female 26 28.0 -2.0 
Total 56 - - 
 
Table 1B. Chi-Square Test Statistics 
Statistic Participant Gender 
Chi-Square .286 
Degrees of freedom 1 
Asymptotic Significance .593 
 
The mean age of participants in the experimental group was 64.14 years (SD = 17.90,  
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min = 26, max = 93). The mean age of participants in the control group was 63.25 years (SD = 
12.69, min = 25, max = 87). The mean years of education for participants in the experimental 
group was 13.93 (SD = 2.80). The mean years of education for participants in the control group 
was 13.57 (SD = 2.20). Descriptive statistics for age and education of each group are reported 
below in Table 2. 
Table 2. Descriptive Statistics for Age and Education 
Variable Group n M(SD) Median Min Max Skewness 
Age Experimental 28 64.14(17.90) 66 26 93 -0.46 
Control 28 63.25(12.69) 64.5 25 87 -0.94 
Education Experimental 28 13.93(2.80) 12 8 20 0.33 
Control 28 13.57(2.20) 12 12 18 0.82 
 
Cancer Types 
A variety of cancer types were reported by participants. The top three most frequently 
occurring cancer types in the sample were (in descending order): lymphoma (23.2%), breast and 
leukemia (14.3%), followed by individuals with two or more cancer types (10.7%). A frequency 
distribution of sample cancer types is reported below in Graph 1. 
Graph 1. Frequency Distribution of Sample Cancer Types 
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Treatment Duration and Time Since Last Treatment 
The mean length of treatment for the experimental group was 9.68 months for the (SD = 
7.85, min = 2, Max = 36). The mean length of treatment for the control group was 7.73 months 
(SD = 4.01, min = 2, Max = 18). The mean time since last treatment for the experimental group 
was 36.39 months (SD = 25.83, min = less than 1, max = 113). The mean time since last 
treatment for the control group was 27.39 months (SD = 28.62, min = less than 1, max = 130). 
Descriptive statistics for ‘treatment duration’ and ‘time since last treatment’ are reported below 
in Table 3. 
Table 3. Descriptive Statistics for Treatment Duration and Time Since Last Treatment 
Variable Group n M(SD) Median Min Max Skewness 
 
Treatment 
Duration 
(months) 
Experimental 28 9.68(7.85) 6.5 2 36 1.87 
Control 28 7.73(4.01) 6.0 2 18 0.65 
Time Since 
Last Treatment 
(months) 
Experimental 28 26.39(25.83) 18.5 1 113 1.45 
Control 28 27.39(28.62) 16.0 <1 130 1.89 
 
Mental Health Concerns 
 Of the 56 participants, 12 participants (21.43%) reported mental health concerns and 44 
participants (78.57%) reported no mental health concerns at the time of participation. Of the 12 
participants who endorsed current mental health concerns, five reported anxiety, four reported 
depression, and three reported a combination of anxiety and depression. Of the 12 participants 
who endorsed current mental health concerns, six were receiving treatment for mental health 
issues at the time of participation and six were not receiving treatment for mental health issues at 
the time of participation. Of those six participants receiving treatment at the time of participation, 
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four reported pharmacotherapy only and two reported psychotherapy only. These data, and their 
relative representation in each group (experimental or control) are shown below in Table 4. 
Table 4. Mental Health by Group 
Variable Group n 
 
Percent of Total 
Sample (n = 56) 
 
Mental Health Concerns at Time of 
Participation 
Total n = 12  
(21.43% of total sample of n = 56) 
 
Experimental 4 7.14 
Control 8 14.29 
Anxiety 
n = 5 
 
Experimental 3 5.36 
Control 2 3.57 
Depression 
 n = 4 
 
Experimental 1 1.79 
Control 3 5.36 
Anxiety and Depression 
n = 3 
 
Experimental 0 0 
Control 3 5.36 
Receiving Treatment 
n = 6 
 
Experimental 3 5.36 
Control 3 5.36 
No Treatment 
n = 6 
 
Experimental 1 1.79 
Control 5 8.93 
Pharmacotherapy only 
n = 4 
 
Experimental 1 1.79 
Control 3 5.36 
Psychotherapy only 
n = 2 
 
Experimental 1 1.79 
Control 1 1.79 
 
 
I. The Effect of Group on Self-Reported Cognitive Functioning as measured by the FACT-
Cognitive, Version 3 (FACT-Cog, V3) 
The FACT-Cog consists of 4 independent subscales: 1) ‘Perceived Cognitive 
Impairments’, 2) ‘Comments From Others’, 3) ‘Perceived Cognitive Abilities’, and 4) ‘Impact 
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On Quality Of Life.’ Four comparisons were planned, thus a Bonferroni adjustment to alpha was 
obtained (.05/4 = .0125 = .013) to minimize the risk of Type I error.  
1. ‘Perceived Cognitive Impairments’  
An independent samples t-test revealed no significant difference in the mean scores on 
the Perceived Cognitive Impairments subscale of the FACT-Cog, V3 for the experimental (M = 
51.04, SD = 19.20) and control (M = 50.32, SD = 14.76) groups; t(54) = 0.16, p = .44,  
d = .04. In other words, those in the experimental group did not report significantly more 
problems with cognitive functioning than the control group. The results, along with the means 
and standard deviations for the two groups, are reported below in Table 5. 
2. ‘Comments from Others’  
 An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 14.68, SD = 2.83) control groups (M = 14.26, SD = 3.01) on the 
Comments From Others subscale of the FACT-Cog, V3, t(53) = .53, p = .30, d = .15. This result 
indicated that those in the experimental group did not report significantly more comments from 
others about their cognitive functioning than the control group. The results, along with the means 
and standard deviations for the two groups, are reported below in Table 5. 
3. ‘Perceived Cognitive Abilities’  
An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 19.19, SD = 7.37) and control groups (M = 19.19, SD = 5.31) on the 
Perceived Cognitive Abilities subscale of the FACT-Cog, V3, t(51) = -.004, p = .50,  
d = .001. This finding demonstrated that those in the experimental group did not report 
significantly fewer cognitive abilities than the control group. The results, along with the means 
and standard deviations for the two groups, are reported below in Table 5. 
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4. ‘Impact on Quality of Life’  
 An independent samples t-test was revealed no significant difference in the mean scores 
for the experimental (M = 11.93, SD = 4.72) and control groups (M = 11.50, SD = 5.22) on the 
Impact on Quality of Life subscale of the FACT-Cog, V3, t(51) = .31, p = .39, d = .09. This 
result revealed those in the experimental group did not report a significantly greater negative 
impact on quality of life than the control group. The results, along with the means and standard 
deviations for the two groups, are reported below in Table 5. 
Table 5. FACT-Cog, V3 Subscale Scores by Group 
FACT-Cog, V3 
Subscales* Group n M(SD) t p d 
 
Perceived Cognitive 
Impairments 
 
Experimental 28 51.04 (19.20) .16 .44 .04 
Control 28 50.32 (14.76) - - - 
 
Comments From 
 Others 
 
Experimental 28 14.68 (2.83) .53 .30 .15 
Control 27 14.26 (3.01) - - - 
 
Perceived Cognitive 
Abilities 
 
Experimental 27 19.19 (7.37) -.004 .50 .001 
Control 26 19.19 (5.31) - - - 
 
Impact On Quality 
Of Life 
 
Experimental 27 11.93 (4.72) .312 .39 .09 
Control 26 11.50 (5.22) - - - 
* For all subscales, higher scores indicate better functioning.  
Alpha = .05/4 = 0.013 = 98.7% Confidence Interval 
Further examination of mean scores on the FACT-Cog, V3 revealed an unexpected 
finding; both groups perceived themselves to have strong cognitive functioning across all four 
subscales. Recall that higher scores indicate better functioning on each subscale of this measure. 
Participants’ mean scores on each subscale of the FACT-Cog, V3 represent a large portion of the 
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total possible score on each subscale. For example, the mean scores for the experimental and 
control groups on the ‘Perceived Cognitive Impairments’ subscale were M = 51 and M = 50, 
respectively. The highest possible score on this subscale representing the highest possible level 
of functioning is 72. Therefore, the mean scores for the experimental group (M = 51) and the 
control group (M = 50) represent 71% and 70% of the highest possible score on this subscale. 
This pattern of strong ratings continued across the other three subscales of the FACT-Cog, V3. 
Mean scores and relative percentages for each group on each subscale of the FACT-Cog, V3, as 
well as maximum scores possible per subscale are reported below, in Graph 2. 
Graph 2. Mean Scores on Functional Assessment of Cancer Therapy-Cognitive, Version 3 
(FACT-Cog, V3) Subscales by Group 
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1. ‘Perceived Impairments During Treatment’ 
An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 3.96, SD = 1.99) and control groups (M = 4.81, SD = 1.73) on the item 
that asked participants to rate their endorsement of negative cognitive symptoms during 
treatment on the Perceived Impairments Scale, t(53) = -1.69, p = .05, d = .45. The results, along 
with the means and standard deviations for the two groups, are reported below in Table 7. 
2. ‘Perceived Impairments After Treatment’  
An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 3.54, SD = 2.12) and control groups (M = 3.89, SD = 1.99) on the item 
that asked participants to rate their endorsement of a stereotype after treatment on the Perceived 
Impairments Scale, t(53) = -.64, p = .26, d = .17. The results, along with the means and standard 
deviations for the two groups, are reported below in Table 7. 
Table 7. Perceived Impairments Scale Scores by Group 
*Perceived 
Impairments Scale 
Items Group n M (SD) t p d 
Degree of perceived 
impairments during 
treatment 
Experimental 28 3.96 (1.99) -1.69 .05 .45 
Control 27 4.81 (1.73) - - - 
 
Degree of perceived 
impairments after 
treatment 
Experimental 28 3.54 (2.12) -.64 .26 .17 
Control 27 3.89 (1.99) - - - 
*For both items, higher scores indicate stronger identification with the CRCI stereotype.  
Alpha = .05/2 = 0.0250 = 0.025 = 97.50% Confidence Interval 
Additional examination of the mean scores on both items of the Perceived Impairments 
Scale offered a second unexpected finding. Both groups endorsed a fair amount of identification 
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with the stereotype of decreased cognitive functioning both during and after chemotherapy. This 
finding contrasts with patients’ high levels of self-reported cognitive functioning on the FACT-
Cog. Mean scores for the experimental and control groups on item 1: ‘Degree of Perceived 
Impairments During Treatment’ were M = 5 and M = 4, respectively. The highest possible score 
on this item is 7 (indicating strong identification with the stereotype). Thus, the mean scores for 
the experimental group (M = 5) and the control group (M = 4) represent 71% and 57% of the 
total possible score on this item. A similar pattern appeared for item 2: ‘Degree of Perceived 
Impairment After Treatment. It is worth noting that scores did not decrease from Item 1 to Item 2 
for the experimental group, while scores did decrease for the control group.  Mean scores and 
relative percentages for each group on both items of the Perceived Impairments Scale, as well as 
maximum scores possible per item are reported below, in Graph 4. 
Graph 4. Mean Scores on Both Items of the Perceived Impairments Scale 
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Score’ were selected for analyses. Three comparisons were planned, thus a Bonferroni 
adjustment to alpha was obtained (.05/3 = .0166 = .017) to minimize the risk of Type I error. 
1. ‘Physician Communication’  
An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 33.27, SD = 5.84) and control groups (M = 33.61, SD = 3.45) on the 
Physician Communication Subscale of the FACIT-TS-PS, V4, t(54) = -.27, p = .40, d = .07. In 
other words, the experimental group did not report significantly less satisfaction with physician 
communication than the control group. The results, along with the means and standard deviations 
for the two groups, are reported below in Table 6. 
2. ‘Treatment Staff Communication’ 
An independent samples t-test revealed no significant difference in the mean scores for 
the experimental (M = 9.71, SD = 3.33) and control groups (M = 9.78, SD = 2.79) on the 
Physician Communication Subscale of the FACIT-TS-PS, V4, t(53) = -.08, p = .47, d = .02. This 
result indicated that the experimental group did not report significantly less satisfaction with 
treatment staff communication than the control group. The results, along with the means and 
standard deviations for the two groups, are reported below in Table 6.  
3. ‘Total Score’ 
An independent samples t-test revealed no significant difference in the total scores for the 
experimental (M = 59.55, SD = 10.03) and control groups (M = 60.32, SD = 6.95) on the FACIT-
TS-PS, V4, t(54) = -.33, p = .37, d = .09. This finding demonstrated that the experimental group 
did not report significantly less overall treatment satisfaction than the control group. The results, 
along with the means and standard deviations for the two groups, are reported below in Table 6. 
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Table 6. FACIT-TS-PS, V4 Subscale Scores by Group 
FACIT-TS-PS, 
V4 Subscales* Group n M(SD) t p d 
 
Physician 
Communication 
 
Experimental 28 33.27 (5.84) -.27 .40 .07 
Control 28 33.61 (3.45) - - - 
 
Treatment Staff 
Communication 
 
Experimental 28 9.71 (3.33) -.08 .47 .02 
Control 27 9.78 (2.79) - - - 
 
Total Score 
 
Experimental 28 59.55 (10.03) -.33 .37 .09 
Control 28 60.32 (6.95) - - - 
* For all subscales, higher scores indicate better functioning.  
Alpha = .05/3 = 0.0166 = 0.017 = 98.3% Confidence Interval 
Like the high ratings seen on the FACT-Cog, ratings on the FACIT-TS-PS, V4 were also 
high, indicating that patients in both groups were highly satisfied with their treatment. Moreover, 
both groups’ mean scores on each subscale of the FACIT-TS-PS, V4 represent a relatively larger 
portion of the total possible score on each subscale than that demonstrated on the FACT-Cog. 
Mean scores and relative percentages for each group on each selected subscale of the FACIT-TS-
PS, V4, as well as maximum scores possible for those subscales are reported below, in Graph 3. 
Graph 3. Mean Group Scores on Selected Subscales of the Functional Assessment of Chronic 
Illness Therapy-Treatment Satisfaction-Patient Satisfaction, Version 4 (FACIT-TS-PS, V4) 
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Discussion 
Results of this study did not support hypotheses that stated that negative expectations 
would lower patients’ self-reports of health-related functioning. Participants scores on the four 
subscales of the FACT-Cog, V3, indicated no significant differences between the groups in their 
perceptions of cognitive impairments, comments from others, their quality of life, and of their 
cognitive abilities.  
However, data from this study revealed an unexpected contrast in how patients rated their 
cognitive functioning on the FACT-Cog, V3 compared with how they rated their cognitive 
functioning on the Perceived Impairments Scale. On the FACT-Cog, V3 patients in both groups 
reported few negative cognitive symptoms, while on the Perceived Impairments Scale, patients 
in both groups identified with the experience of negative cognitive symptoms both during and 
after chemotherapy. Several factors may have contributed to this puzzling finding. First, the 
Perceived Impairments Scale expressly refers to the relationship between chemotherapy and 
negative cognitive symptoms, while the FACT-Cog, V3 does not. The Perceived Impairments 
Scale commences with a definition of chemotherapy-related cognitive impairment that serves to 
overtly draw patients’ attention to the relationship between chemotherapy and cognitive 
symptoms. Second, immediately after patients’ read that definition they were asked to rate how 
strongly they identified with the experience of negative cognitive symptoms during and after 
their treatment with chemotherapy. One conclusion that can be drawn is that these features 
resulted in greater prime intensity on the Perceived Impairments Scale and this drove higher 
scores on this measure compared to scores on the FACT-Cog, V3. Research has shown that 
different levels of prime strength can differentially affect self-report (Simmons, C. M., 2010; 
Kang, S. K., Galinsky, A. D., Kray, L. J., & Shirako, A., 2015). This is not to say that patients’ 
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responses on the FACT-Cog, V3 were based on zero prime. Other factors (such as cancer 
survivor status) could theoretically contribute to a general or broad sense of threat while 
completing the FACT-Cog, V3. However, it seems likely that individuals would experience less 
threat activation on a measure that does not overtly attempt to activate it, and more threat 
activation on a measure that overtly attempts to activate it.  
In addition to ‘prime intensity’, ‘prime familiarity’ may have played a role in higher 
scores on the Perceived Impairments Scale. Research in social psychology has demonstrated that 
familiarity with a stereotype can serve to reinforce that stereotype (Häfner, M., & Stapel, D. A., 
2009; Wen, F., Zuo, B., 2008). As individuals who had completed chemotherapy, patients were 
likely familiar with the CRCI stereotype through their own experience, conversations with 
medical providers, other patients, family, and friends (Schagen, S. B., Das, E., & Van Dam, Frits 
S. A. M, 2009). The brief, bite-sized and familiar chemotherapy heuristic provided at the start of 
the Perceived Impairments Scale could have initiated recognition of that stereotype, thus leading 
participants to endorse that heuristic at higher levels than their scores on the FACT-Cog, V3 
demonstrated (Häfner, M., & Stapel, D. A., 2009; Wen, F., Zuo, B., 2008). In other words, 
patients’ endorsement of the stereotype may have been due to their familiarity with the CRCI 
stereotype (which they were reminded of immediately before responding) rather than their actual 
experience with negative cognitive symptoms.  
The ideas mentioned above, prime intensity and prime familiarity, can be directly applied 
to care in real-world treatment settings. These ideas suggest that how others (professionals, other 
patients, family, and friends) share information with cancer patients about potential side effects 
of treatment or query them about their cognitive functioning could influence their perceptions of 
their functioning and consequently their responses on self-report measures. Research that 
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examines stereotype propagation supports this idea (Clarkson, J. J., Tormala, Z. L., Rucker, D. 
D, 2008; Clarkson, J. J., Tormala, Z. L., Rucker, D. D., & Dugan, R. G., 2013). For example, 
Clarkson, Tormala, and Rucker (2008) showed that when group consensus regarding a stereotype 
was high, individuals rated that stereotype as more “correct” than when group consensus was 
low. In this study, the CRCI stereotype was presented to participants under high consensus 
conditions, i.e., as part of an official study taking place at their treatment clinic, authorized by 
their own oncologist. These conditions may have suggested to participants that a larger group of 
oncologists and researchers likely endorsed the existence of cognitive impairments during and 
after chemotherapy, leading them to agree with the stereotype. Therefore, care must be taken in 
the design of self-report measures and in routine interactions with cancer patients to avoid 
unintentional reinforcement of unhelpful stereotypes.  
While stereotype threat research has mainly examined the role of negative expectations 
on performance, much is yet to be learned about other possibilities such as whether patients’ 
perceptions or attitudes about their cognitive functioning could be boosted through positive 
priming. The beneficial effects of positive priming were demonstrated in a study by Aisenberg 
and colleagues (2015) whereby elderly adults performed better on a cognitive task after receiving 
a positive prime that highlighted participants’ cognitive abilities (rather than the association 
between older age and cognitive decline. Helping cancer patients to understand the temporary 
nature of cognitive symptoms (if they are even experienced) and the degree to which everyday 
cognitive failures (normal, minor thinking errors) occur, may serve to boost perceptions of 
functioning and ultimately minimize or prevent fears related to cognition after chemotherapy. 
For example, forgetting where the car keys were placed likely represents a normal thinking error 
and not cognitive decline associated with chemotherapy.  
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It is also possible that order effects played a role in participants’ relative endorsement of 
the CRCI stereotype versus symptoms on the FACT-Cog.  The Perceived Impairments Scale was 
not included in the Latin Square technique used to order the measures to avoid interference with 
the experimental manipulation. Instead, the Perceived Impairments Scale always occurred in the 
final position, therefore patients always completed it last. Patients may have been ambivalent or 
fatigued by the time they reached the final measure and therefore may have given mid-range 
responses to speed completion or to simplify decision-making. These are not uncommon 
occurrences on questionnaires or on Likert-type scales (Huang, J. L., Liu, M., & Bowling, N. A. 
2015; Raaijmakers, Q. A. W., van Hoof, A., Hart, H. '., Verbogt, T. F. M. A., & Vollebergh, W. 
A. M., 2000). 
Further examination of scores on the Perceived Impairments Scale presented another 
interesting finding: only the control group reported that their cognitive symptoms decreased over 
time. The experimental group reported no such decrease; they reported experiencing the same 
level of identification with the CRCI stereotype after treatment as they experienced during 
treatment. This result is in opposition to the idea that patients are more likely to report a decrease 
in negative cognitive symptoms following treatment than during treatment (Wefel, J. S., Saleeba, 
A. K., Buzdar, A. U., Meyers, C. A., 2010; Raffa, R. B., 2011).  For those in the experimental 
condition, the original experimental manipulation paired with the additional salience of the CRCI 
stereotype may have reinforced patients’ perceptions of cognitive impairment. Research has 
demonstrated that increasing the number of exposures to a prime through repetition can lead to 
greater effects on dependent measures (Smith, E. R., Miller, D. A., Maltner, A. T., Crump, S. A., 
Garcia-Marques, T., & Mackie, D. M., 2006; Wen, F., & Zuo, B., 2008). This finding suggests 
that treatment threat may have actually occurred for the experimental group because it follows 
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the expected pattern of threat activation followed by endorsement of negative cognitive 
symptoms; in this case, negative cognitive symptoms that did not decrease over time as they did 
for the control group. Put in the context of treatment, repeated mention of the “chemo-brain” 
stereotype, from multiple sources could potentially prime patients to perceive their cognitive 
functioning as diminished. This intriguing finding suggests an excellent starting point for further 
investigation. 
As noted earlier, the primary hypotheses of the study were not supported by the data. 
Primary hypotheses postulated that the manipulation (activating treatment threat) would cause 
the experimental group to self-report more negative cognitive symptoms (as measured by the 
FACT-Cog, V3) and less treatment satisfaction (as measured by the FACIT-TS-PS, V4) than the 
control group. These results do not echo results from multiple studies that have shown that 
negative stereotypes can negatively influence performance (Croizet & Claire, 1998; Levy, 1996; 
Spencer, Steele, & Quinn, 1999; Suhr & Gunstad, 2002; Suhr & Gunstad, 2005; Steele & 
Aronson; 1995, & Steele, 1997).  
Examination of data from the FACT-Cog, V3 indicate that across all four subscales, 
participants in both groups reported strong cognitive functioning. Similarly, data across the 
FACIT-TS-PS indicated a high degree of treatment satisfaction. In other words, treatment threat, 
if it was produced at all, did not negatively influence self-reports of health-related functioning 
for this sample of patients, at this specific clinic.  Several methodological issues may have 
contributed to these results.  
One primary methodological explanation may be related to the process of threat 
induction. Other studies examining the phenomenon of stereotype and diagnosis threat have had 
different levels of success in activation of a threat in participants (Suhr and Gunstad; 2005; 
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Trontel, H. G., Hall, S., Ashendorf, L., O’Connor, M. K., 2013). Trontel and colleagues (2013) 
demonstrated that while diagnosis threat was not shown to negatively impact neuropsychological 
test performance, diagnosis threat did lower reports of academic self-efficacy in a traumatic brain 
injury (TBI) population.  Put simply, threat activation can lead to variable effects. As was 
previously mentioned, differences in prime intensity (such as a ‘high intensity prime’ vs. a ‘low 
intensity prime’) can produce differences in degree of threat activation (Simmons, C. M., 2010; 
Kang, S. K., Galinsky, A. D., Kray, L. J., & Shirako, A., 2015).	Logic would suggest that the 
largest effects would stem from high intensity primes; however, the low intensity level of the 
prime in the present study was intentionally selected to prevent emotional distress or feelings of 
conflict in survivors regarding their prior treatment with chemotherapy. Thus,	statements 
intended to activate threat in the experimental group may not have been of sufficient intensity to 
produce clear effects on either the FACT-Cog or the FACIT-TS-PS. 
A second methodological issue may have been related to the recruitment process. All 
participants were recruited during their regularly scheduled maintenance appointments with their 
treating oncologist, therefore, all participants knew they were being recruited due to a prior 
diagnosis of cancer, and by extension, treatment with chemotherapy. Consequently, there may 
not have been a “true” control group. In a sense, all participants may have been primed to some 
degree prior to self-report, which may have produced comparable results between the groups on 
the FACT- Cog,V3. Likewise, check-up appointments where extremely good news is delivered 
(such as stable blood counts and continued remission), may serve to block attempts to induce 
threat. Indeed, overt or strong attempts to persuade others from a currently held belief have been 
shown to backfire (Tormala, Z. L., & Petty, R. E., 2002). Tormala and Petty (2002) investigated 
the effects of resisting persuasion on attitude certainty and found that when the persuasive 
	 39	
attempt was perceived to be strong, participants’ degree of certainty about their own belief not 
only increased, but also limited their vulnerability to persuasive attempts in the future.  
Another potential problem was small sample size. In the design of this project, several 
factors were attempted to be weighed and balanced carefully. On one hand, larger sample sizes 
allow researchers to more easily detect effects if they are present (Hayes, W. L., 1994), however, 
a larger patient sample was not feasible in this study given constraints around access to patients 
and the limited number of physicians who chose to recruit participants. On the other hand, two 
influential and frequently cited papers that examined diagnosis threat in different patient 
populations found significant results with small sample sizes (Suhr, J. A., & Gunstad, J., 2002; 
Suhr, J. A., & Gunstad, J., 2005). This project was completed with this research in mind and with 
the desire to potentially expand the limited information known about the mechanisms that 
underlie the “chemo-brain” stereotype.  
Lastly, differences in cancer type, cancer stage, and treatment protocols could have 
influenced results. These variables were not controlled to maximize the sample size of this 
project. It is easy to imagine how these variables might influence patients’ perceptions of not 
only their cognitive functioning, but other types of functioning as well. For example, an 
individual who experienced an early stage cancer, was treated with less cytotoxic chemotherapy, 
and experienced a shorter treatment duration may report fewer cognitive complaints and better 
overall functioning than an individual who experienced a more severe diagnosis and more trying 
treatment conditions (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou, & Kalofonos, 
2011; de Ruiter et al., 2011).  
While numerous methodological variables may have contributed to the results of the 
study, other “patient-related” variables may also have been at play. Findings in this study may be 
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related to a unique quality or set of qualities possessed by this sample of patients that contributed 
to their ability to repel threat. All participants were cancer survivors, and as such, they may have 
developed strong beliefs and attitudinal characteristics that aided survival following a life-
threatening diagnosis. The emotional and physical challenges of cancer treatment may instill in 
patients, certain beliefs and characteristics that buffered them from successful threat induction. 
Research on posttraumatic growth after cancer indicates that survivors frequently report 
enhanced self-esteem, greater life appreciation and meaning, heightened spitituality, and 
heightened benefit-finding following their cancer experience (Andrykowski, M. A., Lykins, E., 
& Floyd, A., 2008). Results from a study by Schagen, Das, & van Dam (2009) supports the idea 
that treatment experience may inoculate patients to some extent against threat. Schagen and 
colleagues demonstrated that patients with little to no knowledge about CRCI (those who have 
had no experience with treatment or exposure to this idea through family and/or friends) may be 
more vulnerable to the experience of the ‘chemo-brain’ stereotype than patients with knowledge 
of CRCI (those who have had experience with treatment and exposure to this idea through family 
and/or friends). Stated in reverse, Schagen and colleagues found that those with more knowledge 
were less vulnerable, and this may have been the case for patients in the present study. Other 
examples of the effect of attitudes on health outcomes are numerous; for example, optimism, has 
been shown to be positively correlated with better treatment outcomes in cardiac patients and 
others with chronic illness (Corace, K. M., & Endler, N. S., 2003; Hurt, C. S., Burn, D. J., 
Samuel, M., Wilson, K., & Brown, R., G., 2014).  
In addition to patient-related variables, “provider-related” variables may have helped 
patients defend against negative expectations and stereotypes. Consistent with patterns of 
performance on the FACT-Cog, V3, scores on the FACIT-TS-PS, V4 revealed that participants 
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in both groups were highly satisfied with the treatment they received. The FACIT-TS-PS 
included items such as, ‘Did your doctor show genuine concern for you?’; ‘Were you 
encouraged to participate in decisions about your health care?’; and ‘Did the treatment staff 
discuss how your health and treatment may affect you emotionally?’ Participants in both groups 
indicated that they received as much physician and treatment staff communication as they 
wanted and that the quality of their communication was very high. High quality interactions with 
their physicians and other treatment staff may have infused patients with “protection” from 
alternative information that may carry a negative valence (such as negative expectations and 
stereotypes). Studies have shown that high quality physician-patient and nurse-patient 
interactions can increase patients’ confidence in the success of their treatment and create 
increased levels of hope for the future (Charlton, C. R., Dearing, K. S., Berry, J. A., & Johnson, 
M. J., 2008; Merckaert, I., Libert, Y., & Razavi, D., 2005).  
 Results from this study illustrate the challenges involved in investigating chemotherapy-
related cognitive impairment. Often, patients’ subjective reports of their cognitive functioning 
suggest more impairment than that which is observed by objective measurement. Methodological 
issues such as differences in cancer type, treatment type, treatment intensity, measurement 
shortcomings, and lack of baseline data have been implicated as causes of disparate findings. 
The purpose of this study was to investigate a phenomenon that may influence 
performance on subjective measures of functioning. It was proposed that negative expectations 
related to the “chemo-brain” stereotype have the power to negatively influence self-perceptions 
of cognitive functioning (and perhaps other types of health-related functioning) in cancer 
survivors. While the manipulation did not cause the experimental group to report significantly 
more negative cognitive symptoms and less treatment satisfaction, other valuable findings 
	 42	
emerged. Namely, that on one measure patients did identify fairly strongly with the experience of 
negative cognitive symptoms during and after treatment, yet on another measure, they reported 
very few negative cognitive symptoms. It may be that patients were psychologically buffered 
from treatment threat by the attitudes and beliefs that developed through the challenges of coping 
with a life-threatening illness, and/or by the strength of their relationships with their care 
providers.  However, results on the Perceived Impairments Scale suggest that any protective 
effect of a psychological buffer diminished under the influence of increasing prime intensity, 
prime familiarity, and prime repetition and ultimately led participants in the experimental group 
to rate the degree to which they identified with the CRCI stereotype at a moderate level. 
Providing patients with a definition and then asking them if their experience fits that definition, 
could lead them to identify more strongly with that definition or, in this case, the CRCI 
stereotype.   
Conclusion 
 The findings reported here contribute to a growing scientific understanding of the 
underlying mechanisms of chemotherapy-related cognitive impairment. Advances in early 
diagnosis and treatment have resulted in many more people surviving a diagnosis of cancer 
today, than just a short time ago (American Cancer Society, 2014). As the number of survivors 
continues to grow, issues related to survivorship will become increasingly important. The 
prevalence of negative cognitive symptoms reported by patients (up to 68%), makes this issue an 
important topic for consideration by the research community (Ahles & Saykin, 2007; Johnston, 
2014; Joly, Rigal, Noal, & Giffard, 2011; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, 
& Talmi, 2014; Shilling, Jenkins, & Trapala, 2006). Understanding the factors that influence 
perceived cognitive functioning may facilitate the development of intervention programs that 
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aim to prevent or moderate the development of unhelpful stereotypes. Eliminating unhelpful 
stereotypes as factors that influence patients’ attitudes and beliefs about their functioning, may 
ultimately contribute to enhanced quality of life after cancer. 
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Appendix A 
Demographic Questionnaire 
 
INSTRUCTIONS:  Please complete the following screening questionnaire by filling in the 
blanks or circling your answers. 
 
Age: _________________  Birthdate: _________________ 
 
1. Were there any known difficulties with your birth?           Yes     No 
If yes, describe: _____________________________________________________________ 
2. Do you have a vision problem that requires corrective lens wear (e.g., glasses)?      Yes     No 
 
Education  
 
3. Did you ever have to repeat any grades?                   Yes     No 
4. Were you ever placed in special education classes?           Yes     No 
5. What is the highest level of education you have attained (circle one)? 
  
 High School Some college  College degree    Master’s degree Doctoral degree  
 
Medical and Health History 
 
6. Have you ever been diagnosed with any neurological condition?         Yes     No 
 
If yes, please list: ___________________________________________________________ 
 
7. Are you currently experiencing significant problems with your mental health, such as 
problems with anxiety and/or depression, or any other psychiatric condition?         Yes    No 
If yes, please list:  
___________________________________________________________________________
___________________________________________________________________________ 
8. Are you currently receiving treatment for your mental health?          Yes     No 
      If yes, please explain:  
 
______________________________________________________________________________ 
  
______________________________________________________________________________ 
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9. Have you ever felt you should cut down on your drinking/drug use?                     Yes     No 
10. Have you ever been annoyed by people who criticize your drinking/drug use?         Yes     No 
11. Have you ever felt bad or guilty about your drinking or drug use?         Yes     No 
12. Have you ever had a drink first thing in the morning to steady your nerves or         Yes     No 
to get rid of a hangover? 
13. Do you often drive under the influence of alcohol or drugs?          Yes     No 
14. Have you ever been diagnosed with cancer?            Yes     No 
15. If yes, what type of cancer did you have? _________________________________________ 
16. If yes, when were you diagnosed with cancer? _____________________________________ 
17. If yes, how long did your cancer treatment last? ____________________________________ 
18. If yes, what kind of cancer treatment did you receive? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
19. If yes, are you finished will all treatments for this cancer?          Yes     No 
20. If yes, when did you finish all cancer treatments? ___________________________________ 
21. Have you ever experienced a concussion or brain injury?          Yes     No 
22. Were you knocked unconscious?              Yes     No 
If yes, how long were you unconscious? (please circle the letter that corresponds to your 
answer) 
A. Less than 1 minute  
B. 1-30 minutes 
C. More than 30 minutes 
	 61	
23. Do you remember the events before or after your head injury?                                Yes     No 
If no, how long of a time period were you unable to remember? 
1. A few seconds 
2. Less than 5 minutes 
3. Less than 30 minutes 
4. 30 to 60 minutes 
5. More than 60 minutes 
 
           Thank you. 
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Appendix B 
 
Instructions NEG 
 
 
When you finish reading these instructions, sign at the bottom indicating that you have read them and 
understand your task. Then, place this signed sheet back into the envelope, seal it, place an X over 
the seal and wait for the examiner to return.   
 
 
 
You have been invited to participate in this study because you indicated a prior diagnosis of 
cancer and treatment with chemotherapy. A number of studies report that some individuals treated 
with chemotherapy have reported problems with thinking and memory such as feeling forgetful, 
having trouble organizing thoughts, or not being able to think of the right word. Some patients have 
reported that these problems have made other aspects of life (i.e., work, school, home life) more 
difficult. This study will examine the role that chemotherapy may play in numerous areas of health-
related functioning. 
 
When the experimenter returns to the room, s/he will ask you to complete a collection of 
health-related questionnaires.  Please do not leave any questions blank. Some questions may seem 
less applicable to your individual situation. Please choose the response that best represents your 
experience. Please answer as thoroughly and accurately as possible. Questions about individual 
questionnaires will be answered following the testing.	
	
 
 
 
 
I have read these instructions and will do my best to follow them for the remainder of the experiment. 
                                                                         
 
 
_______________________________________________________ 
(Signature) 
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Appendix C 
 
Instructions CG 
 
	
 
When you finish reading these instructions, sign at the bottom indicating that you have read them and 
understand your task.  Then, place this signed sheet back into the envelope, seal it, place an X over 
the seal and wait for the examiner to return. 
	
	
	 	
	
 
When the experimenter returns to the room, s/he will ask you to complete a collection of 
health-related questionnaires. Please do not leave any questions blank. Some questions may seem 
less applicable to your individual situation. Please choose the response that best represents your 
experience. Please answer as thoroughly and accurately as possible. Questions about individual 
questionnaires will be answered following the testing. 
	
	
	
	
 
I have read these instructions and will do my best to follow them for the remainder of the experiment. 
                                                                         
 
 
_______________________________________________________ 
(Signature) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 64	
Appendix D 
	
FACT-Cognitive Function (FACT-Cog), Version 3	
Below is a list of statements that other people with your condition have said are important. Please    
circle or mark one number per line to indicate your response as it applies to the past 7 days. 
 
 
 
 
 
 
 
 
PERCEIVED COGNITIVE IMPAIRMENTS 
Never  About    
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
Several 
times  
a day 
CogA1 I have had trouble forming thoughts ..................................... 0 
 
0 1 2 3 4 
CogA3 My thinking has been slow .................................................... 0 
 
0 1 2 3 4 
CogC7 I have had trouble concentrating ........................................... 0 
 
0 1 2 3 4 
CogM9 I have had trouble finding my way to a familiar 
place ....................................................................................... 0 
 
0 1 2 3 4 
CogM10 I have had trouble remembering where I put things, 
like my keys or my wallet ..................................................... 0 
 
 
0 
 
1 
 
2 
 
3 
 
4 
CogM12 I have had trouble remembering new information, 
like phone numbers or simple instructions  ........................... 0 0 1 2 3 4 
CogV13 I have had trouble recalling the name of an object 
while talking to someone  ......................................................  0 1 2 3 4 
CogV15 I have had trouble finding the right word(s) to 
express myself ....................................................................... 0 
 
0 1 2 3 4 
CogV16 I have used the wrong word when I referred to an 
object ..................................................................................... 0 
 
0 1 2 3 4 
CogV17b I have had trouble saying what I mean in 
conversations with others ...................................................... 0 
 
0 1 2 3 4 
CogF19 I have walked into a room and forgotten what I 
meant to get or do there ......................................................... 0 
 
0 1 2 3 4 
CogF23 I have had to work really hard to pay attention or I 
would make a mistake ........................................................... 0 
 
0 1 2 3 4 
CogF24  
I have forgotten names of people soon after being 
introduced .............................................................................. 0 
 
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
 
Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
 
  Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
 
Several 
times a 
day 
CogF25 My reactions in everyday situations have been 
slow ........................................................................................ 0 
 
0 1 2 3 4 
CogC31 I have had to work harder than usual to keep track 
of what I was doing ............................................................... 0 
 
0 1 2 3 4 
CogC32 My thinking has been slower than usual ............................... 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 1 2 3 4 
CogC33a I have had to work harder than usual to express 
myself clearly ........................................................................ 0 
 
0 1 2 3 4 
CogC33c I have had to use written lists more often than 
usual so I would not forget things ......................................... 0 0 1 2 3 4 
CogMT1 I have trouble keeping track of what I am doing if I 
am interrupted ........................................................................ 0 0 1 2 3 4 
CogMT2 I have trouble shifting back and forth between 
different activities that require thinking ................................ 0 0 1 2 3 4 
 
 
 
 
 
COMMENTS FROM OTHERS 
Never About 
once a 
week 
Two to 
three 
times a 
week 
Nearly 
every 
day 
 
Several 
times a 
day 
CogO1 Other people have told me I seemed to have trouble 
remembering information ...................................................... 0 
 
0 1 2 3 4 
CogO2 Other people have told me I seemed to have trouble 
speaking clearly ..................................................................... 0 
 
0 1 2 3 4 
CogO3 Other people have told me I seemed to have trouble 
thinking clearly ...................................................................... 0 
 
 
 
 
 
 
 
 
 
0 1 2 3 4 
CogO4 Other people have told me I seemed confused ............... 
 
0 1 2 3 4 
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Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
 
 
Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
 
 
  
PERCEIVED COGNITIVE ABILITIES 
Not 
at all 
A little 
bit 
Some-
what 
Quite
a bit 
Very 
much 
 
Cog
PC1 
I have been able to concentrate ...................................................... 0 1 2 3 4 
Cog
PV1 
I have been able to bring to mind words that I wanted to 
use while talking to someone ......................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
Cog
PM1 
I have been able to remember things, like where I left 
my keys or wallet ........................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
Cog
PM2 
I have been able to remember to do things, like take 
medicine or buy something I needed ............................................. 
 
0 
 
1 
 
2 
 
3 
 
4 
Cog
PF1 
I am able to pay attention and keep track of what I am 
doing without extra effort .............................................................. 
 
0 
 
1 
 
2 
 
3 
 
4 
Cog
PCH
1 My mind is as sharp as it has always been ..................................... 0 1 2 3 4 
Cog
PCH
2 My memory is as good as it has always been ................................ 0 1 2 3 4 
Cog
PMT
1 
I am able to shift back and forth between two activities 
that require thinking ....................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
Cog
PMT
2 
I am able to keep track of what I am doing, even if I am 
interrupted ...................................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
  
IMPACT ON QUALITY OF LIFE 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
CogQ3
5 I have been upset about these problems ................................ 0 
 
0 1 2 3 4 
CogQ3
7 These problems have interfered with my ability to 
work ....................................................................................... 0 
 
0 1 2 3 4 
CogQ3
8 These problems have interfered with my ability to 
do things I enjoy .................................................................... 0 
 
0 1 2 3 4 
CogQ4
1 These problems have interfered with the quality 
of my life ............................................................................... 0 
 
0 1 2 3 4 
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Appendix E 
  
FACIT-Treatment Satisfaction-Patient Satisfaction (FACIT-TS-PS), Version 4 
These questions are about the quality of the health care services you are currently receiving. All of 
your responses will be kept confidential. Please mark one answer for each of the following 
questions. Pleasecircle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
 
 
Physician Communication 
No, not at 
all 
Yes, but 
not as 
much as I 
wanted 
Yes, 
almost as 
much as I 
wanted 
Yes, and 
as much 
as I 
wanted 
TS9 Did your doctor(s) give explanations that you could 
understand? ...................................................................  
 
0 
 
1 
 
2 
 
3 
TS10 Did your doctor(s) explain the possible benefits of 
your treatment? .............................................................  
 
0 
 
1 
 
2 
 
3 
TS11 Did your doctor(s) explain the possible side effects 
or risks of your treatment? ............................................  
 
0 
 
1 
 
2 
 
3 
TS12 Did you have an opportunity to ask questions? ............  0 1 2 3 
TS13 Did you get to say the things that were important to 
you? ............................................................................  
 
0 
 
1 
 
2 
 
3 
TS14 Did your doctor(s) seem to understand what was 
important to you? ........................................................  
 
0 
 
1 
 
2 
 
3 
TS15 Did your doctor(s) show genuine concern for you? ...  0 1 2 3 
TS16 Did your doctor(s) seem to understand your needs? ..  0 1 2 3 
TS18 Were you able to talk to your doctor(s) when you 
needed to? ...................................................................  
 
0 
 
1 
 
2 
 
3 
TS27 Were you encouraged to participate in decisions 
about your health care? ..................................................  
 
0 
 
1 
 
2 
 
3 
TS28 Did you have enough time to make decisions about 
your health care? ............................................................  
 
0 
 
1 
 
2 
 
3 
TS30 Did your doctor(s) seem to respect your opinions? .......  0 1 2 3 
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 Treatment Staff Communication No, not 
at all 
Yes, but 
not as 
much as I 
wanted 
Yes, 
almost as 
much as I 
wanted 
Yes,  
and as 
much as I 
wanted 
TS19 Did the treatment staff discuss how your health and 
treatment may affect your normal work (including 
housework)? ....................................................................  
 
 
0 
 
 
1 
 
 
2 
 
 
3 
TS20 Did the treatment staff discuss how your health and 
treatment may affect your normal daily activities? .........  
 
0 
 
1 
 
2 
 
3 
TS21 Did the treatment staff discuss how your health and 
treatment may affect your personal relationships? ..........  
 
0 
 
1 
 
2 
 
3 
TS22 Did the treatment staff discuss how your health and 
treatment may affect you emotionally? ...........................  
 
0 
 
1 
 
2 
 
3 
 
Technical Competence 
No, not 
at all 
Yes, but 
not as 
much as I 
wanted 
Yes, 
almost as 
much as I 
wanted 
Yes,  
and as 
much as I 
wanted 
TS23 Did you feel your doctor(s) had experience treating 
your illness? ...................................................................  
 
0 
 
1 
 
2 
 
3 
TS24 Did you feel your doctor(s) knew about the latest 
medical developments for your illness? ........................  
 
0 
 
1 
 
2 
 
3 
TS25 Was the treatment staff thorough in examining and 
treating you? ..................................................................  
 
0 
 
1 
 
2 
 
3 
 
 
Nurse Communication 
 
No, not at 
all 
Yes, but 
not as 
much as I 
wanted 
Yes, 
almost as 
much as I 
wanted 
Yes, and 
as much 
as I 
wanted 
TS31 Did your nurse(s) give explanations that you could 
understand? ....................................................................  
 
0 
 
1 
 
2 
 
3 
TS32 Did your nurse(s) show genuine concern for you? ........  0 1 2 3 
TS33 Did your nurse(s) seem to understand your needs? .......  0 1 2 3 
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Confidence and Trust 
No, not 
at all 
Yes, but 
not as 
much as 
I wanted 
Yes, 
almost as 
much as 
I wanted 
Yes, and as 
much as I 
wanted 
TS34 Did you feel that the treatment staff answered your 
questions honestly? .....................................................  
 
0 
 
1 
 
2 
 
3 
TS35 Did the treatment staff respect your privacy? .............  0 1 2 3 
TS36 Did you have confidence in your doctor(s)? ..............  0 1 2 3 
TS37 Did you trust your doctor(s)' suggestions for 
treatment? ...................................................................  
 
0 
 
1 
 
2 
 
3 
 
 
Overall 
No Maybe Yes 
TS38 Would you recommend this clinic or office to 
others? ......................................................................  
 
0 
 
1 
 
2 
TS39 Would you choose this clinic or office again? ........  0 1 2 
 
 
 
  
Poor Fair Good Very 
Good 
Excellent 
TS40 How do you rate the care you received? ................  0 1 2 3 4 
 
 
Thank you! Do you have any comments?  
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Appendix F 
 
Perceived Impairments Scale  
  
Current research on cancer recovery describes chemotherapy-related cognitive impairment as the 
experience of having problems with attention, concentration, and memory during and following 
treatment with chemotherapy. Due to these problems, some individuals treated with 
chemotherapy have reported difficulty returning to the activities of daily living following 
treatment, like following medication regimens, managing medical appointments, returning to 
work or school, managing a household, and other activities that require multitasking skills. 
 
 
How accurately does this description represent your experience during chemotherapy (circle 
one)? 
 
 
1                        2                         3                         4                        5                         6                        7 
Not accurately           Perfectly 
at all             accurately 
                             
            
 
 
 
How accurately does this description represent your experience after chemotherapy (circle 
one)? 
 
 
1                        2                         3                         4                        5                         6                        7 
Not accurately           Perfectly 
at all             accurately 
  	
	
Comments: 
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Appendix G 
Debriefing Statement 
 
Thank you for participating in this study.  Throughout the course of this experiment, you may 
have had questions regarding the nature or purpose of this study.  If you still have these 
questions, the experimenter will be glad to answer them for you at this time.   
 
The purpose of this study was to investigate the influence of negative expectations on symptom 
reporting. Specifically, this study was interested in examining whether or not drawing your 
attention to your previous diagnosis of cancer and your treatment with chemotherapy influenced 
your performance on subjective measures of functioning. Your answers to these questions, as 
well as your performance on the testing measures, will be kept completely confidential. 
 
Although a slight amount of discomfort is normal, if you experienced a significant amount of 
discomfort during the course of the experiment, please address your concerns to the experimenter 
at the present time.  If you feel uncomfortable doing so, you may contact the faculty supervisor 
of the project, Dr. Stuart Hall, at 243-5667. If you experience significant discomfort and would 
like to explore counseling or mental health services, students can be seen at the Clinical 
Psychology Center, at 243-2367 or at Counseling and Psychological Services through the Curry 
Health Center, at 243-4711.  
 
 
IMPORTANT:  
We request that you not discuss the details of this experiment with anyone who may be a future 
participant in the study.  Thank you for your cooperation.   
 
 
 
 
 
 
 
 
 
 
